Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d ′Étude des Tumeurs Uro-Génitales) study
Among patients with renal cell carcinoma (RCC), bone and visceral metastases have a poor prognosis, while endocrine gland metastases have a more favorable prognosis. Gastrointestinal metastases (GIMs) are rare, and their prognosis is still poorly understood. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: F. Carneiro, A. Vinceneux, M. Larroquette, M. Rony, L. Carril, B. Laguerre, I. Blazevic, P. Bartelemy, D. Teyssonneau, M. Goujon, C. Linassier, A. Thiery-Vuillemin, G. Roubaud, L. Mourey, L. Albiges, G. Gravis, M. Gross-Goupil, M. Cancel Tags: Original research Source Type: research
Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
In monarchE, abemaciclib demonstrated a sustained benefit in invasive disease-free survival and a tolerable safety profile at 42-months median follow-up. With no expected disease-related symptoms, therapies in the adjuvant setting should preserve quality of life (QoL). With all patients off abemaciclib, we report updated patient-reported outcomes (PROs) for the full 2-year treatment period and follow-up. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Sara M. Tolaney, Valentina Guarneri, Jae Hong Seo, Josefina Cruz, Miguel Henriques Abreu, Masato Takahashi, Carlos Barrios, Kristi McIntyre, Ran Wei, Maria Munoz, Belen San Antonio, Astra M. Liepa, Miguel Martin, Stephen R.D. Johnston, Pirkko-Liisa Kellok Tags: Original Research Source Type: research
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations
The efficacy of checkpoint inhibitors for non-small cell lung cancer (NSCLC) with MET exon 14 skipping (MET Δ14ex) remains controversial. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Miriam Blasi, Jonas Kuon, Heike L üders, Daniel Misch, Diego Kauffmann-Guerrero, Moritz Hilbrandt, Daniel Kazdal, Roger-Fei Falkenstern-Ge, Björn Hackanson, Sebastian Dintner, Martin Faehling, Martina Kirchner, Anna-Lena Volckmar, Hans-Georg Kopp, Micha Tags: Original Research Source Type: research
Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer: A Long Way to Go
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Pengyue Zhao, Songyan Li, Xiaohui Du Tags: Letter to the Editor Source Type: research
Gastrointestinal metastases in renal cell carcinoma: a retrospective multicenter GETUG (Groupe d ’Étude des Tumeurs Uro-Génitales) study
Among patients with renal cell carcinoma (RCC), bone and visceral metastases have a poor prognosis, while endocrine gland metastases have a more favorable prognosis. Gastrointestinal metastases (GIMs) are rare, and their prognosis is still poorly understood. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: F Carneiro, A Vinceneux, M Larroquette, M Rony, L Carril, B Laguerre, I Blazevic, P Bartelemy, D Teyssonneau, M Goujon, C Linassier, A Thiery-Vuillemin, G Roubaud, C Chevreau, L Albiges, G Gravis, M Gross Goupil, M Cancel Tags: Original Research Source Type: research
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
The programmed death 1 inhibitor toripalimab plus the angio-immuno kinase inhibitor surufatinib revealed a tolerable safety profile and preliminary efficacy in patients with advanced solid tumours in a phase I study. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Panpan Zhang, Si Shi, Jianming Xu, Zhendong Chen, Lijie Song, Xing Zhang, Ying Cheng, Yanqiao Zhang, Feng Ye, Zhiping Li, Fei Yin, Dongmei Ji, Heli Gao, Yi Li, Wei Chen, Minjie Yang, Desheng Weng, Chunjiao Wu, Yue Ma, Wang Sheng, Yaqin Zhao, Xiaolei Yin, Tags: Original Research Source Type: research
Efficacy of Immune Checkpoint Inhibitors for Metastatic Colorectal Cancer with Microsatellite Instability in Second or Latter Line Using Synthetic Control Arms: A non-Randomised Evaluation
Immune checkpoint inhibitors (ICIs) appeared active in single-arm trials for patients with chemoresistant metastatic colorectal cancer (mCRC) harboring microsatellite instability (MSI). Given the paucity of randomised controlled trials (RCTs) in this setting, we evaluated the effect size of ICIs using intra-patients comparison and ARCAD database as historical controls. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 14, 2024 Category: Cancer & Oncology Authors: Romain Cohen, Morteza Raeisi, Benoist Chibaudel, Takayuki Yoshino, Qian Shi, John R. Zalcberg, Richard Adams, Chiara Cremolini, Axel Grothey, Robert J. Mayer, Eric Van Cutsem, Josep Tabernero, Hideaki Bando, Toshihiro Misumi, Michael J Overman, Thierry An Tags: Original Research Source Type: research
Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: a nationwide study
The clinical significance of tumor-positive peritoneal cytology (CYT+) in gastric cancer (GC) patients is unclear. This nationwide cohort study aimed to i) assess the frequency of cytological analysis at staging laparoscopy; ii) determine the prevalence of CYT+ GC; and iii) compare overall survival (OS) in CYT+ patients versus those with (PM+) and those without (PM-) macroscopic peritoneal disease. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 14, 2024 Category: Cancer & Oncology Authors: Karen Van Der Sluis, Steven N. Taylor, Liudmila L. Kodach, Jolanda M. van Dieren, Ignace H.J.T. de Hingh, Bas P.L. Wijnhoven, Rob H.A. Verhoeven, Marieke A. Vollebergh, Johanna W. van Sandick Tags: Original Research Source Type: research
Prediction of prognosis and treatment response in ovarian cancer patients from histopathology images using graph deep learning: a multicenter retrospective study
Ovarian cancer (OV) is a prevalent and deadly disease with high mortality rates. The development of accurate prognostic tools and personalized therapeutic strategies is crucial for improving patient outcomes. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2024 Category: Cancer & Oncology Authors: Zijian Yang, Yibo Zhang, Lili Zhuo, Kaidi Sun, Fanling Meng, Meng Zhou, Jie Sun Tags: Original Research Source Type: research
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
Pembrolizumab has a manageable safety profile as described in its label, which was primarily based on 2799 patients who participated in clinical trials for melanoma or non-small cell lung cancer. Here, we evaluated the safety of pembrolizumab in a broader population of patients from 31 advanced cancer clinical trials across 19 cancer types. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 11, 2024 Category: Cancer & Oncology Authors: Julie R. Brahmer, Georgina V. Long, Omid Hamid, Edward B. Garon, Roy S. Herbst, Thierry Andre, Philippe Armand, Dean Bajorin, Joaquim Bellmunt, Barbara Burtness, Toni K. Choueiri, Ezra E.W. Cohen, Luis A. Diaz, Kohei Shitara, Girish Kulkarni, David McDerm Tags: Original Research Source Type: research
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
The primary analysis of the phase III NIBIT-M2 study showed a 41% 4-year overall survival (OS) of melanoma patients with asymptomatic brain metastases treated with ipilimumab plus nivolumab. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 10, 2024 Category: Cancer & Oncology Authors: Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Elena Simonetti, Federica Santangelo, Giovanni Amato, Alessia Covre, Roberto Camerini, Monica V Tags: Original Research Source Type: research
Effect of High-field iMRI Guided Resection in Cerebral Glioma Surgery: A Randomized Clinical Trial
Extent of resection (EOR) in glioma contributes to longer survival. The purpose of NCT01479686 was to prove whether intraoperative magnetic resonance imaging (iMRI) increases EOR in glioma surgery and benefit survival. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 8, 2024 Category: Cancer & Oncology Authors: Zeyang Li, Yanyan Song, N.U. Farrukh Hameed, Shiwen Yuan, Shuai Wu, Xiu Gong, Dongxiao Zhuang, Junfeng Lu, Fengping Zhu, Tianming Qiu, Jie Zhang, Abudumijiti Aibaidula, Xu Geng, Zhong Yang, Weijun Tang, Hong Chen, Liangfu Zhou, Ying Mao, Jinsong Wu Tags: Original Research Source Type: research
Incidence, clinical management and prognosis of patients with small intestinal adenocarcinomas from 1999 through 2019: a nationwide Dutch cohort study
Small intestinal adenocarcinomas (SIAs) are rare. Hence, randomized controlled trials are lacking and understanding of the disease features is limited. This nationwide cohort investigates incidence, treatment and prognosis of SIA patients, to improve disease outcome. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 8, 2024 Category: Cancer & Oncology Authors: Tim R. de Back, Jasmijn D.G. Linssen, Felice N. van Erning, Caitlin S.E. Verbakel, Pascale J.M. Schafrat, Louis Vermeulen, Ignace de Hingh, Dirkje W. Sommeijer Tags: Original Research Source Type: research
Shrinking sample sizes in lung cancer trials: Various explanations, open questions
In patients with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable mutation, checkpoint inhibitor therapies (CPI), have become the backbone of the first-line therapy [1]. However, many patients don ’t benefit from it, with their prognosis remaining rather poor once reached second line. During 2023, three randomized clinical trials (RCT) in this setting were reported, in which the sample size was reduced during accrual. Here we discuss the reasons for those decisions and their potential impli cations in interpreting trials’ results. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 6, 2024 Category: Cancer & Oncology Authors: Timoth ée Olivier, Alfredo Addeo Tags: Letter to the Editor Source Type: research
Cancer screenings in Poland. A call to the new government and health minister for informed leadership
On November 1st, 2023, Poland underwent a significant recalibration of age criteria for cancer screenings, signifying a pivotal shift in preventive healthcare. This adjustment particularly impacts early detection initiatives for breast and cervical cancers, showcasing a deliberate effort to enhance public health outcomes. In breast cancer screening, the age range expanded, allowing women aged 45-74 biennial access to complimentary mammography, contrasting the previous 50-69 years with a two-year screening interval. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 6, 2024 Category: Cancer & Oncology Authors: Pawe ł Koczkodaj, Irmina Maria Michalek Tags: Letter to the Editor Source Type: research
